[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"suicidality\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:suicidality":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,74,104,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100616183","analysis-of-suicidal-behavior-among-children-and-adolescents-in-the-auvergne-rhone-alpes-region-during-the-covid-19-pandemic-period-100616183",false,"NCT07302295","Analysis of Suicidal Behavior Among Children and Adolescents in the Auvergne-Rhone-Alpes Region During the Covid 19 Pandemic Period","Clinical and Socioeconomic Characteristics of Suicidal Behaviour in Children and Adolescents During the Covid19 Pandemic Period in Auvergne-Rhône-Alpes. Prospective Quantitative and Qualitative Study","TSPedCovid","Inclusion Criteria:\n\n* The population (subjects and controls) will be divided into age categories:\n\n  * Pre-adolescents (≥ 8 years and \\\u003C 11 years)\n  * Adolescents (≥ 11 years and \\\u003C 15 years)\n  * Older adolescents (≥ 15 years and \\\u003C 18 years)\n\nSubjects with suicidal behavior during the health crisis (Group 1):\n\n* Age \\> 8 years and \\\u003C 18 years during the period 2020 to 2022.\n* Admitted to pediatric emergency departments or hospitalized in a care unit (CHU, general hospitals) in the AURA region during 2020, 2021, and\u002For 2022 for suicidal behavior (defined as suicidal ideation and\u002For suicide attempt and\u002For self-harm\u002Fself-poisoning with suicidal intent).\n\nSubjects with suicidal behavior during the health crisis with qualitative interviews (Group 1b):\n\n* Age \\> 8 years and \\\u003C 18 years during the period 2020 to 2022.\n* Admitted to pediatric emergency departments or hospitalized in a care unit (CHU, general hospitals) in the AURA region during 2020, 2021, and\u002For 2022 for suicidal behavior (defined as suicidal ideation and\u002For suicide attempt and\u002For self-harm\u002Fself-poisoning with suicidal intent).\n* Randomly selected from the population of Group 1.\n* For whom the parent(s) and\u002For the subject have signed informed consent.\n\nControls with suicidal behavior before the health crisis (Group 2):\n\n* Age \\> 8 years and \\\u003C 18 years during the period 2018 to 2019.\n* Admitted to pediatric emergency departments or hospitalized in a care unit (CHU, general hospitals) in the AURA region during 2018 and\u002For 2019 for suicidal behavior (defined as suicidal ideation and\u002For suicide attempt and\u002For self-harm\u002Fself-poisoning with suicidal intent).\n\nExclusion Criteria:\n\n\\- Subjects with Suicidal Behavior during the Health Crisis with and without Qualitative Interviews (Group 1 and 1b):\n\n• Admitted to pediatric emergency services or hospitalized in a healthcare facility (university hospital center, general hospital) in the AURA region for a psychiatric reason other than suicidal behavior during the period from 2020 to 2022.\n\nControls with Suicidal Behavior before the Health Crisis (Group 2):\n\n* Admitted to pediatric emergency services or hospitalized in a healthcare facility (university hospital center, general hospital) in the AURA region for a psychiatric reason other than suicidal behavior during the period from 2018 to 2019.\n* Intercurrent illness with a life expectancy of less than 24 hours.\n\nFor Group 1:\n\n* Pregnant, postpartum, or breastfeeding women.\n* Persons deprived of liberty by judicial or administrative decision.\n* Adults subject to a legal protection measure (guardianship, curatorship).\n* Persons not affiliated with a social security scheme or beneficiaries of a similar scheme.\n* Persons who do not understand and do not speak French.","ALL","8 Years","18 Years",{"count":21,"type":22},6500,"ESTIMATED","INTERVENTIONAL",[25],"NA","In 2020, the world is hit by a global health crisis due to a pandemic following the appearance of Sars-cov-2 or \"covid-19\". This pandemic was accompanied by a constant fear of contamination and death, relayed by the media. In France, the government proposed in response to the arrival of this virus on French territory. This policy was implemented in different ways over 3 distinct periods: strict containment at the start of the epidemic, then a \"lighter\" one, and finally a period of social restrictions without between these periods. This policy had a direct and rapid impact on the population's daily routines. Children and adolescents, are more susceptible to psychological trauma, as stress has a direct and psychic development. Studies have shown deleterious impact of the French health situation on the paediatric population. They point to an increase of psychological disorders such as depression and anxiety in the under -20s population, and an increase in suicidal gestures over the 2020-2021 period, with rates remaining higher than in previous years. Suicide is the 2nd leading cause of death in the population aged 15-24.\n\nStudies continue to focus on the incidence of suicidal gestures of suicidal gestures and psychological disorders, and few of them examine the factors linked to the increase in these incidences, the traumatic impact or the story of the trajectory. Similarly, the few studies focus only on the population aged 12 and over, and in some cases, do not distinguish between age groups (15-24 or under 20).\n\nInvestigators believe that the various periods of social restrictions and eco-anxiety caused by the pandemic may have influenced suicidal behaviour in this population.\n\nThe main objective of this study is to investigate the clinical and socio-economic characteristics of the pediatric population who experienced suicidal behaviors in the Auvergne Rhone Alpes region during the covid 19 pandemic.",[28,29],"Suicidality","COVID -19",[31,32,33],"suicide","pediatrics","covid-19","RECRUITING","2026-05-15",{"date":37,"type":38},"2026-05-18","ACTUAL",{"date":40,"type":38},"2026-05-06",{"date":42,"type":22},"2028-02",{"name":44,"class":45},"Hospices Civils de Lyon","OTHER",4,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100565230","assessing-improvements-in-mood-and-sleep-trial-100565230","NCT06639477","Assessing Improvements in Mood and Sleep Trial","Multi-site Randomized Controlled Trial Comparing the Efficacy of Behavioral Approaches to Improve Mood and Sleep in Adults","AIMS","Inclusion Criteria:\n\n* Age 55 Years and older\n* Patient Health Questionnaire -9 score of 10 or higher\n* Past month Scale for Suicide Ideation score of 3 or higher OR any history of suicide attempt\n* PROMIS Sleep Disturbance or impairment scale t-scores of 55 or higher\n* Pharmacotherapy for depression meeting minimum adequate dose level as defined by FDA approval documents for at least 4 weeks.\n\nExclusion Criteria:\n\n* Active suicide planning with intent or clinical judgement that suicide risk is too high for outpatient treatment OR being currently treated at an inpatient unit.\n* Bipolar disorder\n* Psychotic disorder\n* Borderline personality disorder.\n* Active Cognitive\u002FBehavioral Therapy (e.g., CBT-I), current or upcoming esketamine (ketamine) treatment, or active phase of ECT\u002FTMS treatment course.\n* Illness with life expectancy of less than 1 year or plans to leave the study area\n* Incapacity to consent\u002Fdementia diagnosis\n* Active substance use disorder of at least moderate severity\n* Active night-shift work\n* Any physical, mental, or neurological condition that would make participation in the study, including either treatment arm, unsafe or infeasible.","55 Years",{"count":57,"type":22},420,[25],"This is a multi-site randomized control trial involving people age 55+ years who have current depression symptoms plus another suicide risk indicator (either current suicidal ideation or a past history of attempt). Our goal is evaluate which of two different approaches works best to improve things like trouble sleeping, bad moods, and any suicidality.\n\nParticipants will complete diagnostic interviews, self-report scales, and wear an actigraphy device for the 8 weeks starting at the baseline visit.",[61,28,62],"Depression","Sleep",[64,61],"Older Adults",{"date":66,"type":38},"2026-05-19",{"date":68,"type":38},"2025-05-20",{"date":70,"type":22},"2030-08",{"name":72,"class":45},"University of Pittsburgh",3,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100625251","phase-2-sleep-health-in-us-marines-100625251","NCT07420205","Sleep Health in U.S. Marines","Reducing Suicidality Through Improved Sleep Health","Inclusion Criteria:\n\n* Age 18+\n* Able to read and write in English\n* Currently serving as an active duty member of the U.S. Marine Corp\n* Currently assigned to duty at the approved study site\n\nExclusion Criteria:\n\n* Planned deployment or training operation lasting 30 days or longer and \u002For planned change of duty station within the study period (i.e., 24 weeks postrecruitment)\n* Under 18 years of age\n* Unable to read and write in English",true,{"count":83,"type":22},860,[85],"PHASE2","The goal of this study is to test a sleep health program designed specifically for U.S. Marine Corps personnel. Researchers want to determine if this program helps Marines improve the participants sleep quality and overall mental health. The study will evaluate whether the program improves sleep quality and duration and reduces symptoms of depression, anxiety, PTSD, and suicide ideation. There are three distinct sleep health programs that will be evaluated; participants will be randomly assigned to one of five groups to receive different combinations of the sleep health programs. To measure results, researchers will use participant surveys for all enrolled participants and wearable sleep-tracking devices for a sub-set of participants. The study team expects that Marines who receive the most comprehensive version of the program will show the greatest improvements in sleep and psychological well-being.",[61,28,62],[62,89,90,91,28,92,93],"Psychological Health","U.S. Military","United States Marine Corps","Sleep Health","Health Promotion","2026-04-14",{"date":96,"type":38},"2026-04-16",{"date":98,"type":38},"2026-03-31",{"date":100,"type":22},"2027-06",{"name":102,"class":45},"San Diego State University",1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":103},"100570360","phase-2-acceptability--safety-of-two-sequential-doses-of-psilocybin-in-bipolar-disorder-ii-depression-and-suicidality-100570360","NCT06706232","Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality","Inclusion Criteria:\n\n* Must have completed written informed consent\n* Must be at 25 years of age or older at screening (but below age of 70)\n* Confirmed Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of BD-II using clinical records and Diagnostic Interview for Anxiety, Mood, and Obsessive-compulsive disorder (OCD) and Related Neuropsychiatric Disorders (DIAMOND)\n* Must meet criteria for suicidality according to the INQ cutoff scores: A score of at least 12 on the Perceived Burden (PB) subscale and at least a score of 36 on the Thwarted Belongingness (TB) subscale indicating substantial risk for passive suicidal ideation\n* Must meet criteria for depression according to the MADRS cutoff scores: A score of 7-34 indicating mild to moderate depression\n* Must pass medical examination (physical exam, personal\u002Ffamily medical history, including consultation with current medical provider, ECG, about 4 tablespoons blood draw, psychiatric\u002Fpsychological assessments, urine drug test)\n* Willingness to taper down mood stabilizers and other relevant medications (including but not limited to: antidepressants, antipsychotics, lithium, benzodiazepines, Monoamine oxidase inhibitors (MAOIs), Selective serotonin reuptake inhibitors (SSRIs), Serotonin and norepinephrine reuptake inhibitors (SNRIs), A serotonin-norepinephrine-dopamine reuptake inhibitors (SNDRIs), Tricyclic antidepressants (TCAs), stimulants, cannabis, and other medications, supplements or therapeutics that affect serotonergic function) for the duration of the study before and during administration days (starting 5 weeks before administration), and be off medication for at least 2 weeks prior to administration\n* Willingness to stop allowed medication at least 24 h prior to administration of psilocybin as advised by study physician (e.g., benzodiazepines)\n* Ability to complete all protocol required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits\n\nExclusion Criteria:\n\n* Participants who do not read\u002Fspeak English\n* Active suicidal ideation with at least some intent and\u002For plan (i.e., a current score of 4 or 5 on the C-SSRS)\n* History of medically significant suicide attempt in the last 6 months\n* Current or past history of Bipolar I disorder, psychotic symptoms or psychotic disorder, (including but not limited to schizophrenia, delusional disorder, schizoaffective disorder) clinically relevant personality disorder (such as borderline, antisocial, narcissistic or paranoid personality disorder), or any serious psychiatric comorbidity considered negatively impacting participation or safety (e.g., PTSD or severe substance use or alcohol disorder) assessed by medical history and\u002For a structured clinical interview\n* Have a first or second degree relative with Bipolar I disorder or a psychotic disorder\n* Currently experiencing a hypomanic or mixed-symptom episode\n* Have a psychiatric or other condition judged to be incompatible with establishment of rapport or safe exposure to psilocybin\n* Any indication of a Personality Disorder (PD) such as but not limited to Borderline, Narcissistic, Antisocial, Paranoid, or Schizotypal PD based on Structured Clinical Interview for DSM-5 for PD and\u002For clinical judgment","25 Years","70 Years",{"count":113,"type":22},10,[85],"The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.",[117,118,28],"Bipolar II Disorder","Depression, Bipolar",[120,121],"Bipolar II Depression","Psilocybin","2025-07-15",{"date":124,"type":38},"2025-07-18",{"date":126,"type":38},"2025-07-07",{"date":128,"type":22},"2027-01",{"name":130,"class":45},"The University of Texas Health Science Center, Houston",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":149,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":158,"leadSponsor":160,"locationsCount":103},"100564990","phase-2-nitrous-oxide-in-the-treatment-of-acute-suicidal-ideation-100564990","NCT06636357","Nitrous Oxide in the Treatment of Acute Suicidal Ideation","NITOS","Inclusion criteria:\n\n* Ability to give written informed consent\n* Moderate to severe suicidal ideation defined as a score ≥3 on the Montgomery-Asberg Depression Rating Scale (MADRS; Schmidtke et al., 1985) suicide item (item #10) as well as a self-report Beck Scale for Suicide Ideation (BSS; Kliem et al., 2017) items #4 plus #5 score ≥ 2\n* Plasma homocysteine level ≤ 14 µmol\u002Fl\n\nExclusion criteria:\n\n* Organic, including symptomatic, mental disorders (F00-F09; lifetime diagnosis)\n* Schizophrenia, schizotypal and delusional disorders (F20-F29; lifetime diagnosis)\n* Mental and behavioral disorders due to psychoactive substance use. Nicotine and cannabis will be ignored (F10-F19)\n* Non-medical (i.e., recreational) use of inhalational N2O during the last 12 months\n* Past intolerance or hypersensitivity to N2O\n* Critical illness\n* Severe cardiac disease\n* Pregnancy or breastfeeding\n* Pulmonary hypertension\n* Chronic cobalamin or folate deficiency unless treated with folic acid and\u002For vitamin B12\n* History or evidence of any other medical or neurological condition that would expose the subject to an undue risk of a significant adverse event as determined by the clinical judgment of the investigator\n* Treatment with ketamine\u002Fesketamine during the last 4 weeks\n* Treatment with opioid medications during the last 3 months\n* Treatment with vagus nerve stimulation (VNS) or electroconvulsive therapy (ECT) within the last 3 months\n* Recent (within the last 4 weeks) or current use of benzodiazepines in excess of 5 mg lorazepam or equivalent per day\n* Finally, any other factors that, in the investigator's judgment, would unduly impact patient safety or compliance during the study.","65 Years",{"count":140,"type":22},85,[85],"The primary aim of the NITOS study is to investigate the potential rapid antisuicidal effects of N2O in the transdiagnostic treatment of suicidal ideation. On day 1, patients will receive either nitrous oxide (50% N2O balanced with oxygen) or placebo (50% oxygen balanced with air). Seven days after the first inhalation, a second inhalation will be performed. All patients will receive N2O at least once during this trial. While the first inhalation will be double-blind, only the patients but not the raters will be blinded to the second inhalation (day 8). For mechanism of action and prediction, a nested biomarker substudy will employ multimodal techniques including analysis of hair and blood samples, and EEG.",[28,144,145,146,147,148],"EEG","Suicidal Ideation","Nitrous Oxide","Biomarkers \u002F Blood","Biomarkers \u002F Hair",[150,151,152,153],"suicidality","nitrous oxide","suicidal ideation","depression","2025-01-13",{"date":156,"type":38},"2025-01-16",{"date":154,"type":38},{"date":159,"type":22},"2026-09-30",{"name":161,"class":45},"University of Zurich"]